BioSpace - Dynavax Technologies Corporation News, Search Jobs, Events

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

Search the Site

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

..

Dynavax Technologies Corporation

2929 Seventh Street
Suite 100
Berkeley California 94710 U.S.A.
Phone: 510-848-5100 Fax: 510-848-1379

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Our clinical-stage product candidates include:

• Phase 3 HEPLISAV ™ Hepatitis B Vaccine
• Phase 1 Universal Flu Vaccine
• Phase 1 Hepatitis C Therapy
• Phase 1 Hepatitis B Therapy

In addition, we have an oligonucleotide-based Toll-like Receptor (TLR) inhibitors, called immunoregulatory sequences (IRS), being readied for clinical studies by the end of 2010. We also have programs partnered with pharmaceutical companies, including AstraZeneca and GlaxoSmithKline.

Our European subsidiary Rhein Biotech manufactures hepatitis B surface antigen for HEPLISAV. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.

For more information, visit www.dynavax.com.

Key Statistics

Email: contact@dynavax.com
Ownership: Public

Web Site: Dynavax Technologies Corporation
Employees:
Symbol: DVAX

Industry
Biopharmaceutical

Segment
Immunotherapeutic Vaccine

Company News

Dynavax Technologies Corporation (DVAX) Reports First Quarter 2013 Financial Results 5/7/2013 10:15:14 AM More...

Dynavax Technologies Corporation (DVAX) Taps GlaxoSmithKline (GSK)'s Eddie Gray as CEO 4/30/2013 7:47:41 AM More...

Dynavax Technologies Corporation (DVAX) Appoints David Novack as Senior Vice President, Operations and Quality 3/22/2013 8:54:57 AM More...

Dynavax Technologies Corporation (DVAX) Reports Fourth Quarter and Year End 2012 Financial Results 3/4/2013 9:16:40 AM More...

Dynavax Technologies Corporation (DVAX) to Present at the Cowen and Company 33rd Annual Healthcare Conference 2/26/2013 9:24:15 AM More...

FDA: Dynavax Technologies Corporation (DVAX) Hep B Vaccine Needs More Evaluation 2/25/2013 7:28:24 AM More...

Dynavax Technologies Corporation (DVAX) to Present at the 31st Annual J.P. Morgan Healthcare Conference 12/17/2012 10:14:04 AM More...

Dynavax Technologies Corporation (DVAX) Reports Third Quarter 2012 Financial Results 11/1/2012 12:45:12 PM More...

Dynavax Technologies Corporation (DVAX) to Initiate Phase 1 Studies for TLR-9 Agonist for Asthma 10/31/2012 11:10:44 AM More...

Dynavax Technologies Corporation (DVAX) Announces FDA Advisory Committee to Review HEPLISAV(TM) 8/28/2012 9:29:21 AM More...

1